Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (784)	2/25/2000 6:07:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

Interesting article in this weeks Science. The technique may one day obviate the need for memantine. But, it is a long, long way off. Nevertheless, it again demonstrates how important control of the NMDA receptor is in brain injury situations. It again suggests that memantine could be a very useful drug for TBI, Stroke, and Epilepsy. Best regards John de C An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy Matthew J. During, Charles W. Symes, Patricia A. Lawlor, John Lin, Jane Dunning, Helen L. Fitzsimons, David Poulsen, Paola Leone, Ruian Xu, Bridget L. Dicker, Janusz Lipski, and Deborah Young sciencemag.org p. 1453 Immunization Against Stroke and Epilepsy --------------------------------------------------------------------------- The N-methyl-D-aspartate (NMDA) receptor is important in brain plasticity and development and may also be involved in the pathology that results from neurological disorders. During et al. (p. 1453; see the news story by Helmuth) have found that immunization of mice with a DNA vaccine encoding the NR1 subunit of the NMDA receptor could induce antibody-mediated, but not cellular, immunity in rats. This treatment induced protective effects against kainate-induced seizures (a model for temporal lobe epilepsy) and endothelin-1-induced middle cerebral artery occlusion (a model for stroke). No effects on movement or behavior were observed. Although long-term effects of such immunization are not yet known, it has the potential of having fewer side effects than pharmacological approaches with NMDA receptor antagonists.